2005

P-glycoprotein deficiency at the blood-brain barrier increases amyloid-β deposition in an Alzheimer disease mouse model

John R. Cirrito
Washington University School of Medicine in St. Louis

Rashid Deane
University of Rochester

Anne M. Fagan
Washington University School of Medicine in St. Louis

Michael L. Spinner
Washington University School of Medicine in St. Louis

Maia Parsadanian
Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Cirrito, John R.; Deane, Rashid; Fagan, Anne M.; Spinner, Michael L.; Parsadanian, Maia; Finn, Mary Beth; Jiang, Hong; Prior, Julie L.; Sagare, Abhay; Bales, Kelly R.; Paul, Steven M.; Zlokovic, Berislav V.; Piwinca-Worms, David; and Holtzman, David M., "P-glycoprotein deficiency at the blood-brain barrier increases amyloid-β deposition in an Alzheimer disease mouse model." The Journal of Clinical Investigation,. 3285-3290. (2005).
https://digitalcommons.wustl.edu/open_access_pubs/1522

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Authors
John R. Cirrito, Rashid Deane, Anne M. Fagan, Michael L. Spinner, Maia Parsadanian, Mary Beth Finn, Hong Jiang, Julie L. Prior, Abhay Sagare, Kelly R. Bales, Steven M. Paul, Berislav V. Zlokovic, David Piwinca-Worms, and David M. Holtzman
Accumulation of amyloid-β (Aβ) within extracellular spaces of the brain is a hallmark of Alzheimer disease (AD). In sporadic, late-onset AD, there is little evidence for increased Aβ production, suggesting that decreased elimination from the brain may contribute to elevated levels of Aβ and plaque formation. Efflux transport of Aβ across the blood-brain barrier (BBB) contributes to Aβ removal from the brain. P-glycoprotein (Pgp) is highly expressed on the luminal surface of brain capillary endothelial cells and contributes to the BBB. In Pgp-null mice, we show that [125I]Aβ40 and [125I]Aβ42 microinjected into the CNS clear at half the rate that they do in WT mice. When amyloid precursor protein–transgenic (APP-transgenic) mice were administered a Pgp inhibitor, Aβ levels within the brain interstitial fluid significantly increased within hours of treatment. Furthermore, APP-transgenic, Pgp-null mice had increased levels of brain Aβ and enhanced Aβ deposition compared with APP-transgenic, Pgp WT mice. These data establish a direct link between Pgp and Aβ metabolism in vivo and suggest that Pgp activity at the BBB could affect risk for developing AD as well as provide a novel diagnostic and therapeutic target.

**Introduction**

Conversion of amyloid-β (Aβ) within the extracellular spaces of the brain into toxic soluble and insoluble forms is accelerated at higher concentrations, implying that pathways influencing Aβ production or elimination could potentially modulate disease progression. Aβ is secreted from neurons into brain interstitial fluid (ISF), where it is eliminated by proteolytic degradation (1, 2), passive bulk flow (3), and active transport across the blood-brain barrier (BBB) (4, 5). The latter, representing efflux across the BBB into the interstitial fluid (ISF), where it is eliminated by proteolytic degradation (1, 2), is secreted from neurons into brain interstitial fluid (ISF) within hours of treatment. Furthermore, APP-transgenic, Pgp-null mice had increased levels of brain Aβ and enhanced Aβ deposition compared with APP-transgenic, Pgp WT mice. These data establish a direct link between Pgp and Aβ metabolism in vivo and suggest that Pgp activity at the BBB could affect risk for developing AD as well as provide a novel diagnostic and therapeutic target.

**Results**

To directly assess the role of Pgp in transport of Aβ across the BBB, we first microinjected [125I]Aβ40 or [125I]Aβ42 into the brains of mdr1a/b−/− double-knockout (Pgp-null) mice and WT controls (7). [14C]inulin, a reference molecule that is neither actively transported across the BBB nor retained within the brain, was coadministered to measure bulk flow of ISF in the same mice. Thirty minutes following coadministration of tracers, mice were sacrificed, and the content of each compound remaining in the brain was assessed (Figure 1, A and C). Significantly more [125I]Aβ40 and [125I]Aβ42 were retained within the brains of Pgp-null animals compared with Pgp WT mice.
Next, we assessed how acute inhibition of Pgp activity affected brain ISF Aβ levels. We utilized APPsw (also called Tg2576) mice, which overexpress human amyloid precursor protein (APP), with a mutation that in humans causes an autosomal dominant form of early-onset familial AD (14). A selective Pgp inhibitor, XR9576 (15), was used to block Pgp activity at the BBB in APPsw mice. Because brain capillary endothelial cells transport molecules out of the brain ISF into the periphery, we directly assessed this fluid to determine whether the absence of Pgp at the BBB caused decreased elimination of Aβ from brain ISF. Ten hours after treatment with either vehicle or XR9576 and continued to assess ISF Aβ levels for an additional 10 hours (Figure 2A). Eight hours after treatment, ISF Aβ levels increased almost 30% compared with vehicle-treated mice (P < 0.05), suggesting that acute inhibition of Pgp at the BBB caused decreased elimination of Aβ from brain ISF. Ten hours after treatment with either vehicle or XR9576, cerebral microvessels were also isolated and assessed for levels of LRP1 by Western blotting. LRP1 levels in endothelial cells did not change (Figure 2B), indicating that, in this case, the change in ISF Aβ levels is not attributable to LRP1 downregulation but is likely due to specific inhibition of Pgp.

Next, we determined whether the absence of Pgp at the BBB would promote Aβ deposition. We bred APPsw (also called Tg2576) mice, which overexpress human amyloid precursor protein (APP), with a mutation that in humans causes an autosomal dominant form of APPsw transgene and either Pgp-null (APPsw –/–, mdr1a/b–/–) or Pgp WT (APPsw +/–, mdr1a/b–/–). To confirm that transgenic expression of mutated human APP did not impact basal function of Pgp in vivo, biodistribution studies utilizing [99mTc]Sestamibi, a radio-

(P = 0.0123 and P = 0.0047, respectively), strongly suggesting that Aβ elimination was hindered in these animals. Removal of [3H]leucine, a Pgp-independent, actively transported molecule, was unaffected at 10 minutes after injection (61.4% ± 3.8% and 62.7% ± 5% retained in Pgp WT [FVB] versus Pgp-null, respectively). Similarly, bulk flow pathways, accounting for less than 20% of clearance, appeared unchanged in the knockout animals as demonstrated by nearly identical levels of inulin remaining in both groups. As shown in Figure 1B, after passive elimination was taken into account, 31% of injected Aβ40 was transported across the BBB in WT mice, whereas only approximately 14% was cleared in the Pgp-null animals (P = 0.0033). Similarly, 16% of Aβ42 was transported across the BBB in WT mice compared with 6% in Pgp-null mice (Figure 1D). Compared with Aβ40, significantly less Aβ42 was removed from the brain in WT and Pgp-null mice, which is consistent with previous studies showing that Aβ40 is generally actively transported across the BBB more than Aβ42 (7). LRP1 has been previously shown to transport Aβ across the BBB (5, 7). While overall levels of LRP1 in brain homogenates did not change (Figure 2B), indicating that, in this case, the change in ISF Aβ levels is not attributable to LRP1 downregulation but is likely due to specific inhibition of Pgp.

Next, we determined whether the absence of Pgp at the BBB would promote Aβ deposition. We bred APPsw (also called Tg2576) mice, which overexpress human amyloid precursor protein (APP), with a mutation that in humans causes an autosomal dominant form of APPsw transgene and either Pgp-null (APPsw –/–, mdr1a/b–/–) or Pgp WT (APPsw +/–, mdr1a/b–/–). To confirm that transgenic expression of mutated human APP did not impact basal function of Pgp in vivo, biodistribution studies utilizing [99mTc]Sestamibi, a radio-

(P = 0.0123 and P = 0.0047, respectively), strongly suggesting that Aβ elimination was hindered in these animals. Removal of [3H]leucine, a Pgp-independent, actively transported molecule, was unaffected at 10 minutes after injection (61.4% ± 3.8% and 62.7% ± 5% retained in Pgp WT [FVB] versus Pgp-null, respectively). Similarly, bulk flow pathways, accounting for less than 20% of clearance, appeared unchanged in the knockout animals as demonstrated by nearly identical levels of inulin remaining in both groups. As shown in Figure 1B, after passive elimination was taken into account, 31% of injected Aβ40 was transported across the BBB in WT mice, whereas only approximately 14% was cleared in the Pgp-null animals (P = 0.0033). Similarly, 16% of Aβ42 was transported across the BBB in WT mice compared with 6% in Pgp-null mice (Figure 1D). Compared with Aβ40, significantly less Aβ42 was removed from the brain in WT and Pgp-null mice, which is consistent with previous studies showing that Aβ40 is generally actively transported across the BBB more than Aβ42 (7). LRP1 has been previously shown to transport Aβ across the BBB (5, 7). While overall levels of LRP1 in brain homogenates did not change (Figure 2B), indicating that, in this case, the change in ISF Aβ levels is not attributable to LRP1 downregulation but is likely due to specific inhibition of Pgp.

Next, we determined whether the absence of Pgp at the BBB would promote Aβ deposition. We bred APPsw (also called Tg2576) mice, which overexpress human amyloid precursor protein (APP), with a mutation that in humans causes an autosomal dominant form of APPsw transgene and either Pgp-null (APPsw –/–, mdr1a/b–/–) or Pgp WT (APPsw +/–, mdr1a/b–/–). To confirm that transgenic expression of mutated human APP did not impact basal function of Pgp in vivo, biodistribution studies utilizing [99mTc]Sestamibi, a radio-

(P = 0.0123 and P = 0.0047, respectively), strongly suggesting that Aβ elimination was hindered in these animals. Removal of [3H]leucine, a Pgp-independent, actively transported molecule, was unaffected at 10 minutes after injection (61.4% ± 3.8% and 62.7% ± 5% retained in Pgp WT [FVB] versus Pgp-null, respectively). Similarly, bulk flow pathways, accounting for less than 20% of clearance, appeared unchanged in the knockout animals as demonstrated by nearly identical levels of inulin remaining in both groups. As shown in Figure 1B, after passive elimination was taken into account, 31% of injected Aβ40 was transported across the BBB in WT mice, whereas only approximately 14% was cleared in the Pgp-null animals (P = 0.0033). Similarly, 16% of Aβ42 was transported across the BBB in WT mice compared with 6% in Pgp-null mice (Figure 1D). Compared with Aβ40, significantly less Aβ42 was removed from the brain in WT and Pgp-null mice, which is consistent with previous studies showing that Aβ40 is generally actively transported across the BBB more than Aβ42 (7). LRP1 has been previously shown to transport Aβ across the BBB (5, 7). While overall levels of LRP1 in brain homogenates did not change (Figure 2B), indicating that, in this case, the change in ISF Aβ levels is not attributable to LRP1 downregulation but is likely due to specific inhibition of Pgp.

Next, we determined whether the absence of Pgp at the BBB would promote Aβ deposition. We bred APPsw (also called Tg2576) mice, which overexpress human amyloid precursor protein (APP), with a mutation that in humans causes an autosomal dominant form of APPsw transgene and either Pgp-null (APPsw –/–, mdr1a/b–/–) or Pgp WT (APPsw +/–, mdr1a/b–/–). To confirm that transgenic expression of mutated human APP did not impact basal function of Pgp in vivo, biodistribution studies utilizing [99mTc]Sestamibi, a radio-
pharmaceutical that has been validated as a sensitive probe of Pgp transport function (18), were performed in 2- to 4-month-old WT (mdr1a/b+/-) and Pgp-null (mdr1a/b-/-) mice, both in the absence and presence of the APPsw+/- transgene. Normally, [99mTc]Sestamibi is readily transported out of the brain by Pgp. However, in Pgp-null animals, [99mTc]Sestamibi levels increase in the brain as it permeates cerebral capillaries and is not removed effectively. Five minutes after intravenous bolus injection of [99mTc]Sestamibi (2 μCi), brain content of the tracer was 0.22% ± 0.02% injected dose/g (ID/g) in WT controls versus 0.85% ± 0.14% ID/g in Pgp-null mice (Figure 3). There was no difference in blood content of the tracer between the 2 strains (P > 0.2). This approximately 3.5-fold increase in brain penetration of [99mTc]Sestamibi in Pgp-null mice was consistent with previous studies (19). In animals of similar age that expressed the APPsw+/- transgene, brain penetration of the tracer was also increased by approximately 3.5-fold in Pgp-null animals compared with those expressing Pgp (Figure 3). Thus, basal activity of Pgp was independent of the APPsw+/- transgene (P > 0.3).

When allowed to survive to 12 months, APPsw+/- mice exhibited substantial Aβ deposition throughout the neocortex and hippocampus (Figure 4A and B). The area covered by Aβ immunoreactivity in the hippocampus was significantly greater in APPsw+/-Pgp-null animals compared with APPsw+/- Pgp WT littermates (P = 0.0041; Figure 4C). The amount of fibrillar Aβ, as determined by thioflavine S staining, was also significantly elevated in Pgp-null animals (P = 0.0276; Figure 4D). However, when the amount of thioflavine S was normalized to total plaque load, there was not a significant difference in the percentage of fibrillar plaques between groups (Figure 4E). This suggests that while Pgp deletion leads to greater Aβ deposition, Pgp does not preferentially alter the conversion of plaques into fibrillar structures. There was no apparent change in the amount of vascular Aβ accumulation in 12-month-old Pgp-null animals; however, it remains possible that at later ages, when there is a greater amount of cerebral amyloid angiopathy, there may be a noticeable effect. The mass of insoluble Aβ42, as assessed by guanidine extraction and Aβ ELISA, was 2-fold greater in the hippocampus of Pgp-null animals (P = 0.0499; Figure 4F), while there was only a trend toward an increase in insoluble Aβ40 (P = 0.2472; Figure 4G). Carbonate-extractable Aβ40 and Aβ42 was not different between these groups (data not shown). Similar to the hippocampus, there was a trend toward elevated Aβ plaque load in the neocortex of Pgp-null mice; however, this increase was not statistically significant (Figure 4H). These findings indicate that abrogation of the Pgp transporter at the BBB gave rise to greater Aβ accumulation within the brain and suggest that modulation of Pgp activity can directly influence progression of Aβ pathology. Because genetic deletion of Pgp also causes a decrease in the level of LRP1 at the BBB (Figure 1), it remains possible that the changes in Aβ deposition are due to a combined decrease in both Aβ transporters. In fact, these Aβ transporters may be playing a synergistic role, with LRP1 functional on the basolateral surface and Pgp on the luminal surface of brain endothelial cells.

Figure 2
Acute inhibition of Pgp increases Aβ levels in brain ISF. Using in vivo microdialysis, we assessed the concentration of ISF Aβ1-42 within the hippocampus of 3-month-old APPsw mice treated with XR9576, a Pgp inhibitor. For each animal, basal concentration of ISF Aβ1-42 was established over 5 hours, followed by intravenous injection of XR9576 and continued assessment of ISF Aβ for an additional 10 hours. Samples were collected at hourly intervals and assessed for Aβ1-42 using a sandwich ELISA. (A) Eight hours after intravenous administration of 80 mg/kg XR9576, ISF exchangeable Aβ1-42 (eAβ1-42) levels began to increase and reached 127.7% ± 3.4% of control-treated (vehicle-treated) mice (*P < 0.05; n = 5 per group). (B) Ten hours after treatment with either XR9576 or vehicle, cerebral capillaries were isolated and analyzed for levels of LRP1 expression by Western blotting (n = 5 per group). Levels of LRP1 in cerebral vessels did not change with acute inhibition of Pgp.

Figure 3
Biodistribution of a Pgp substrate in APPsw, Pgp-null mice. Following tail vein bolus injection of 2 μCi [99mTc]Sestamibi, brain content of [99mTc]Sestamibi in 2- to 4-month-old WT and Pgp-null mice (on an FVB background), as well as APPsw mice expressing or lacking Pgp, was determined 5 minutes after injection. More tracer was retained in all Pgp-null mice (*P = 0.0043, FVB strain; **P = 0.0058, APPsw+/- strain), demonstrating, as expected, that Pgp normally hinders the entry of [99mTc]Sestamibi into the brain. Taken together, these findings suggest that Pgp expressed on the BBB behaves similarly in WT and APPsw mice. ID, injected dose.
Pgp shares sequence homology and substantial pharmacological cross-reactivity with several members of the ATP-binding cassette superfamily of transporters that are also expressed at the BBB, including multidrug-resistance–associated protein-1 (MRP1, also known as \textit{ABCC1}) (9). In 12-month-old APP\textsubscript{sw}, Pgp-null (\textit{APP\textsubscript{sw}}\textsuperscript{+/–}, \textit{mdr1a/b}–/–) mice, expression of MRP1 in hippocampal homogenates was elevated compared with Pgp WT (\textit{APP\textsubscript{sw}}\textsuperscript{+/+}, \textit{mdr1a/b}+/+) mice (\(P = 0.0401\); data not shown). Although Pgp and MRP1 have overlapping pharmacological profiles, it is unknown whether MRP1 can also transport A\textsubscript{β} in vivo. In vitro studies suggest that MRP1 cannot transport A\textsubscript{β} (12). Receptor for advanced glycation endproducts (RAGE), a transporter on the BBB that is responsible for transporting A\textsubscript{β} from the blood into the brain (20, 21), was expressed at similar levels in hippocampal homogenates of 12-month-old APP\textsubscript{sw}, Pgp-null and APP\textsubscript{sw}, Pgp WT mice (data not shown). The potential contribution of each of these transporters to A\textsubscript{β} clearance from the brain and how they might interact or compensate for each other requires further investigation.

**Discussion**

Herein, we demonstrate that Pgp is involved in the transport of A\textsubscript{β} across the BBB in vivo and that ablation of Pgp at the BBB enhances A\textsubscript{β} deposition. While Pgp deletion has not been reported in humans, several mechanisms for modulation of Pgp activity at the BBB could influence AD. Several Pgp single nucleotide polymorphisms, such as the exon 26 3435T allele, have been described that decrease Pgp expression and result in functional differences in oral absorption and disposition of drugs (22). It is conceivable that similar polymorphisms in Pgp could decrease A\textsubscript{β} transport out of the brain, thereby increasing the probability of plaque formation. Conversely, polymorphisms that increase Pgp transport activity may decrease the risk of A\textsubscript{β} deposition and development of AD. A detailed genetic analysis of Pgp polymorphisms in relation to AD in humans could test this hypothesis.

In addition to the impact of genetic polymorphisms on Pgp activity, many commonly used drugs and herbal medicinals alter Pgp function. For example, dexamethasone, morphine, rifampin, quercetin, and St. John’s wort are reported to enhance Pgp activity, while verapamil, cyclosporine A, erythromycin, fluoxetine, progesterone, HIV protease inhibitors, and several statins inhibit Pgp activity (for review, see refs. 9, 23). While some of these compounds only affect Pgp activity slightly in short-term assays, with chronic use or in combination, it is possible that these drugs could have a greater effect on Pgp function and, consequently, on brain A\textsubscript{β} levels. Since Pgp function can be modulated pharmacologically, there is potential for drugs that enhance activity to increase A\textsubscript{β} clearance from the brain.
the brain. For example, a randomized clinical trial demonstrated that the antibiotic rifampin lessened cognitive decline in patients with mild to moderate AD after 12 months of treatment (24). This improvement in cognitive function did not appear to be linked to the drug’s antibiotic activity. Because rifampin is also a Pgp substrate and inducer, the effects of rifampin on cognitive ability may be linked to enhanced clearance of Aβ from the brain via Pgp-mediated transport. An additional advantage of modulating Pgp activity is that because Pgp is expressed on the luminal surface of brain capillary endothelial cells and not within the CNS per se, drugs may not be required to cross the BBB, a typical hurdle in developing CNS-targeted therapies. Given that a variety of genetic, therapeutic, and dietary factors can influence Pgp function, thus potentially affecting Aβ transport, it will be interesting to determine whether these factors correlate with the incidence of AD.

Methods

Animals. All experimental procedures involving animals were approved by the Animal Studies Committee at Washington University and performed in accordance with their guidelines. We utilized 8- to 10-week-old mdr1a/b–/– double-knockout mice on an FVB background (Taconic) and WT controls (also on an FVB background) for our BBB transport studies. We also bred mdr1a/b–/– mice to APPsw/– hemizygous mice (Tg2576 on a C57BL/6SJL background; a generous gift from K. Ashe, University of Minnesota, Minneapolis, Minnesota, USA). We then bred F1 offspring from each colony to produce littermate mdr1a/b homozgyous (+/+) and double-knockout (–/–) mice that were hemizygous for the APPsw/– transgene. Animals were screened for the presence of P-gp as well as mdr1a and mdr1b genes by PCR analysis of tail DNA. Aβ content in the brain was analyzed when animals were 12 months old.

BBB transport. Transport of human [125I]Aβ42 [125I]Aβ40 across the BBB and calculations were performed as previously described (4, 8). Briefly, a guide cannula was implanted stereotaxically into the right cisterna-putamen of anesthetized mice at coordinates 0.9 mm anterior to bregma, 1.9 mm lateral, and 2.9 mm below the dura. Animals were allowed to recover after surgery prior to radiotracer studies. The clearance experiments were performed before substantial chronic processes occurred, typically 4–6 hours following cannula implantation, to allow the BBB to at least partially repair and exclude large molecules (8, 16). Twelve nanomoles of [14C]inulin and either [125I]Aβ40 or [125I]Aβ42 was injected in a volume of 0.5 μl over 5 minutes using an ultra micropump (World Precision Instruments Inc.). The specific activities of peptide were in the range of 80–120 μCi/μg. The percentage of radioactivity remaining in the brain after microinjection was determined as percentage recovery in brain = 100 × (Ni/Ni0), where Ni0 is the radioactivity remaining in the brain at the end of the experiment and Ni is the radioactivity microinjected into brain ISF, i.e., the disintegration per minute for [14C]inulin and the counts per minute for trichloroacetic acid–precipitable [125I]radioactivity (intact Aβ). The percentage of Aβ cleared through the BBB was calculated as ([(1 - Ni(k)/Ni(0)) - (1 - NIN/NI(0))] × 100, using a standard time of 30 minutes. Δ[4.5S]H]leucine (Amersham Biosciences) transport across the BBB was assessed using a method similar to that described above: 750 nmol of [3H]leucine, specific activity 1.6 Ci/mg, was injected in a volume of 0.5 μl followed by measurement of radioactivity within the brain at 10 minutes.

ISF Aβ in vivo microdialysis. In vivo microdialysis were performed as described previously (16, 17). Aβ40+42 represents all Aβ peptides beginning at amino acid 1 of the N-terminus with the C-terminus being variable, but predominantly either ending at position 40 or 42. An initial 4- to 6-hour recovery period elapsed after guide implantation and probe insertion to allow for tissue recovery, followed by collection of microdialysis samples for 5 hours at 1-hour intervals at a flow rate of 1.5 μl/min to establish basal level of ISF Aβ. XR9576 (80 mg/kg body weight; Xenova QLT Inc.; diluted in 5% dextrose) or vehicle was injected into the jugular vein, and an additional 10 one-hour microdialysis samples were collected. Concentrations of ISF Aβ40+42 for each mouse were expressed as the percentage of basal level for each mouse (mean of 5 hours prior to treatment).

Micropuncture and biodistribution. The radiopharmaceutical [99mTc]Sestamibi (Bristol-Myers Squibb Co.) was prepared from a 1-step commercial kit formulation by addition of [99mTcO4]- according to the manufacturer’s recommendations (25). Sep-Pak purification (>95%) and quality control of the tracer were performed as previously described (25). Following intravenous injection, distribution of [99mTc]Sestamibi in the brain and blood of Pgp WT and Pgp-null mice with or without coexpression of APPsw/– was determined 5 minutes after injection as previously described (26, 27). Data are expressed as percent injected dose per gram tissue ([Ci [99mTcSestamibi in tissue] (μCi injected/μCi tissue) × 100]) and are reported as mean ± SEM (n = 3–4) or z range (n = 2).

Histological analysis. Tissue sections were cut in the coronal plane at 50 μm on a freezing sliding microtome from the genu of the corpus callosum through the caudal extent of the hippocampus. The percent surface area covered by Aβ-immunoreactivity deposits (% Aβ load), as identified with a mouse monoclonal antibody against the N terminus of human Aβ, m3D6 (Eli Lilly and Co.), was quantified following unbiased stereological principles as described (28). Thioflavin S staining was performed stereologically and quantified as previously described (29). Aβ and thioflavin S load were determined in the cingulate cortex and hippocampus in 3 brain sections, each separated by 300 μm.

Aβ quantification. Aβ40 levels in brain tissue were determined by sandwich ELISA as previously described (16). Briefly, m266, m2G3, or m21F12 were used as coating antibodies to capture Aβ40, Aβ42, or Aβ42, respectively. Biotinylated m3D6, a human-specific antibody against the N terminus of Aβ, was used as the reporting antibody in each ELISA. To evaluate the carbonate-soluble and -insoluble pools of Aβ in brain tissue, we performed a carbonate extraction (100 mM carbonate, 50 mM NaCl, protease inhibitors, pH 11.5) of hippocampal tissue (1:10, wt/vol) on ice followed by a 5 M guanidine, pH 8.0 extraction for 3 hours at room temp. Tissue samples were dounce homogenized and spun in a microcentrifuge at 21,000 g for 15 minutes at 4°C following each extraction.

Western blotting. Hippocampal tissue from 12-month-old APPsw, Pgp WT, and APPsw, Pgp-null littermates was homogenized in 150 mM NaCl, 50 mM Tris pH 7.4, 0.5% deoxycholic acid, 0.1% SDS, 1% Triton X-100, 2.5 mM EDTA, and protease inhibitors. Western blotting for MRP1, LRP1, and RAGE were performed using 3–8% NuPAGE Tris-Acetate gels (Invitrogen Corp.) with 30 μl of hippocampal tissue (1:10, wt/vol) on ice following each extraction. Proteins were separated by SDS-PAGE, transferred to nitrocellulose membrane, and probed with rabbit anti-MRP1 (Abcam, Cambridge, MA), rabbit anti-LRP1 (Santa Cruz Biotechnology Inc.), or rabbit anti-RAGE (Santa Cruz Biotechnology Inc.). Bands were detected with horseradish peroxidase-conjugated secondary antibodies (Jackson Immunoresearch Laboratories Inc.). Bands were detected using a luminescent imaging system (Amersham Biosciences) and captured digitally using Kodak ImageStation 440CF. The relative absorbance of each band was determined by densitometry and normalized to protein loaded in each lane. Analysis was performed using Kodak 1D Image Analysis software version 3.6.
Acknowledgments

This study was funded by NIH grants AG13956 (to D.M. Holtzman), AG023316 (to A.M. Fagan), P50 CA94056 (to D. Piwnica-Worms), NS034467 (to B.V. Zlokovic), and AG23084 (to B.V. Zlokovic) as well as an Investigator Award from the McDonnell Center for Cellular and Molecular Neurobiology (to A.M. Fagan) and US Department of Energy contract DE FG02 94ER61885 (to D. Piwnica-Worms).

Received for publication April 4, 2005, and accepted in revised form August 23, 2005.

Address correspondence to: David M. Holtzman, Department of Neurology, Washington University School of Medicine, 660 S. Euclid Avenue, Box 8111, St. Louis, Missouri 63110, USA. Phone: (314) 362-9872; Fax: (314) 362-2826; E-mail: holtzman@neuro.wustl.edu. Or to: David Piwnica-Worms, Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 S. Kingshighway Boulevard, Box 8225, St. Louis, Missouri 63110, USA. Phone: (314) 362-9356; Fax: (314) 362-0152; E-mail: piwnica-worms@mir.wustl.edu.

Statistics. Data shown in figures represent mean ± SEM. Mann-Whitney U test was used to compare data between Pgp-null and WT mice, as well as LRP1 expression levels in endothelial cells of X9576 and vehicle-treated mice. ISF Aβ levels in X9576 and vehicle-treated mice, over the duration of the experiment, were compared by 2-way ANOVA followed by the Bonferroni post-hoc test to compare means. P values of less than 0.05 were considered statistically significant. All statistical analyses were performed using Prism version 4.02 (GraphPad Software) for Windows (Microsoft Corp.).